Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Expired

Repurposing Research to Improve Patient Outcomes in Meniere's Disease and Related Diagnoses: Clinical and Preclinical Projects

Cures Within Reach

This Request for Proposals (RFP) from Cures Within Reach (CWR) is seeking collaborative, multisite clinical repurposing trials to address Meniere’s disease, as well as other related vertigo and hearing loss-related diagnoses, such as benign paroxysmal positional vertigo (BPPV), tinnitus, labyrinthitis and vestibular neuritis, to improve patient outcomes and quality of life. CWR may also accept translational preclinical repurposing studies that are designed to advance repurposed therapies to clinical trials or combination preclinical/clinical studies that together produce robust data for publications, presentations, follow on funding and potential off label use of repurposed therapies. Submissions can come from accredited academic, nonprofit and governmental research institutions and/or health systems significantly involved with medical research located anywhere in the world.

CWR is accepting budgets of up to $350,000 for collaborative, multisite clinical trials. CWR may also accept budgets up to $100,000 for translational preclinical studies for this RFP. Submitted budgets must include the required institutional match (see Important Funding Information below). If you have an idea for a preclinical or combination preclinical/clinic study, please contact CWR directly before submitting to discuss fit and/or submission options.

Clinical trial designs should take into account the high placebo effect found in Meniere’s disease research, and all studies should have an experimental design and plan that allows for appropriate statistical analyses and reproducibility of the data.

Specialties

Clinical Trials

Otolaryngology

Eligibility Requirements

Be in Meniere’s disease or other vertigo and hearing loss-related diagnoses such as benign paroxysmal positional vertigo (BPPV), tinnitus, labyrinthitis and vestibular neuritis, and repurpose approved and/or generally recognized as safe drugs, devices or nutraceuticals, either alone or in combination o Repurposed therapies can also be added to current standard of care therapies

• Be collaborative, multisite, interventional clinical trials

o Clinical trial designs should take into account the high prevalence of the placebo effect in Meniere’s disease and related conditions and should use a conservative estimate in the power analysis when determining the sample size needed for statistically significant results

o If you have an idea for a single site interventional clinical trial, please contact CWR for submission options

• Have a timeline of no longer than 48 months for clinical trials or 36 months for preclinical studies

• Be conducted at an accredited academic, nonprofit or governmental research institution and/or health system significantly involved with medical research located anywhere in the world, where good scientific research and clinical practices can be assured o Although start-ups, biotechs, pharmaceutical companies and medical device companies are not eligible for this RFP, their collaborators at eligible institutions can apply

• Be led either by a previously funded investigator or by an early-stage investigator who has received little or no extramural research funding to date

o PIs who have not received extramural funding previously and/or who do not currently have their own lab should include a Letter of Support from a funded, senior researcher who will act as a mentor for the proposed research and the investigator

• Not yet have funding (see Important Funding Information below) or already have funding from another source, when funding from CWR will help improve the chances of success of the project and/or help speed patient impact

Although CWR has a preference for collaborative, multisite clinical trials, we may consider 1) strong, translational preclinical projects that are designed to advance repurposed therapies to clinical trials and that utilize human cell/tissue based systems or 2) combination preclinical/clinical studies that together produce robust data for publications, presentations, follow on funding and potential off label use of repurposed therapies. If you have an idea for a preclinical or combination preclinical/clinic study, please contact CWR directly before submitting to discuss fit and/or submission options.

Sponsor Details

Sponsor Institute/Organizations: Cures Within Reach

Sponsor Type: Corporate/Non-Profit

Address: 134 N. LaSalle, #1130, Chicago, IL 60602

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity